Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis

Publisher: John Wiley & Sons Inc

E-ISSN: 1365-2133|177|6|1562-1574

ISSN: 0007-0963

Source: BRITISH JOURNAL OF DERMATOLOGY, Vol.177, Iss.6, 2017-12, pp. : 1562-1574

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content